Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew J Krentz

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
Expert Opinion on Drug Safety|October 19, 2006
Comparative safety of newer oral antidiabetic drugsAndrew J Krentz
The Practitioner|September 1, 2009
Identifying patients with metabolic syndromeAndrew J Krentz
Evidence-Based Medicine|December 24, 2011
Some oral antidiabetic medications may prevent Type 2 diabetes in people at high risk for it, but the evidence is insufficient to determine whether the potential benefits outweigh the possible risksAndrew J Krentz
Cardiovascular Endocrinology & Metabolism|October 8, 2019
DiRECT and indirect paths to reducing cardiovascular risk in diabetes: insights from Diabetes UK 2019Andrew J Krentz
Journal of the Royal Society of Medicine|May 5, 2006
Self-image in obesity: clinical and public health implicationsAndrew J Krentz
Metabolic Syndrome and Related Disorders|March 29, 2008
Prevention of cardiovascular complications of the metabolic syndrome: focus on pharmacotherapyAndrew J Krentz
Cardiovascular Endocrinology & Metabolism|October 25, 2019
Cardiovascular Endocrinology & MetabolismAndrew J Krentz
Cardiovascular Endocrinology & Metabolism|August 18, 2020
Introduction: cardiometabolic considerations in COVID-19Andrew J Krentz
Drugs|February 1, 2011
Rosiglitazone: trials, tribulations and terminationAndrew J Krentz
Clinical Medicine (London, England)|May 12, 2007
New oral agents for type 2 diabetesAndrew J Krentz
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Expert Opinion on Drug Safety|October 19, 2006
Comparative safety of newer oral antidiabetic drugsAndrew J Krentz
The Practitioner|September 1, 2009
Identifying patients with metabolic syndromeAndrew J Krentz
Evidence-Based Medicine|December 24, 2011
Some oral antidiabetic medications may prevent Type 2 diabetes in people at high risk for it, but the evidence is insufficient to determine whether the potential benefits outweigh the possible risksAndrew J Krentz
Cardiovascular Endocrinology & Metabolism|October 8, 2019
DiRECT and indirect paths to reducing cardiovascular risk in diabetes: insights from Diabetes UK 2019Andrew J Krentz
Journal of the Royal Society of Medicine|May 5, 2006
Self-image in obesity: clinical and public health implicationsAndrew J Krentz
Metabolic Syndrome and Related Disorders|March 29, 2008
Prevention of cardiovascular complications of the metabolic syndrome: focus on pharmacotherapyAndrew J Krentz
Cardiovascular Endocrinology & Metabolism|October 25, 2019
Cardiovascular Endocrinology & MetabolismAndrew J Krentz
Cardiovascular Endocrinology & Metabolism|August 18, 2020
Introduction: cardiometabolic considerations in COVID-19Andrew J Krentz
Drugs|February 1, 2011
Rosiglitazone: trials, tribulations and terminationAndrew J Krentz
Clinical Medicine (London, England)|May 12, 2007
New oral agents for type 2 diabetesAndrew J Krentz
Pageof 5